MC Services is an international Corporate Communications and Investor Relations firm providing Life Sciences companies high-level consultancy, targeted services and support throughout Europe and beyond
Our Services
Public Relations & International Awareness
- Strategy, positioning & messaging
- Corporate communications
- Media relations – local, national, & international
- Thought leadership
- Corporate materials
- Media events
- Media training
- Digital & social media
- Internal communications
- Crisis communications
Corporate & Product Communications Pharma
- Communication strategy
- Top-tier & medical media relations
- Healthcare policy
- communications
- Executive positioning
- KOL & stakeholder engagement
- Scientific & medical writing
- Life cycle communications
- Market access & reimbursement communications
- Patient advocacy
Brand & Marketing
- Brand identity & corporate design
- Brand awareness campaigns
- Lead generation
- Digital marketing
- Website design & development
- Trade shows & events
- Marketing materials
Investor Relations & Access
- Strategic IR consulting
- Equity story development
- Financial communications
- Investor targeting & access
- Investor roadshows & events
- Financial reporting
- IR presentations, websites & other corporate materials
- Financing & capital market transactions
SELECTED CLIENTS – PAST AND PRESENT
Client News
DEBRA Research Invests in Topadur to Advance Small-Molecule Therapies for Dystrophic Epidermolysis Bullosa
CorTec Brain Interface Electrodes Record Stable Signals for More Than Four Years
Formycon and Biocelys Combine Complementary Development and Manufacturing Expertise in New Biosimilar Project FYB286
MC Services is media partner for BIO-Europe 2026
MC Services is proud to once again support BIO-Europe as official media partner. Taking place from November 9–11, 2026, in Cologne, Germany, BIO-Europe is the global strategic biopharma platform where senior industry leaders connect, align on priorities, and advance partnerships.
The 2026 edition will bring together more than 5,800 participants from over 3,200 companies across more than 60 countries, including biotech and pharma executives, investors and strategic partners. While partnering remains central, the program will also address broader industry priorities, from investment and dealmaking to clinical, regulatory and manufacturing strategy.
For more information on the program, timing and additional activities, please visit the event’s website.